New Iqvia tool provides visibility into informed consent

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Fizkes)
(Image: Getty/Fizkes)

Related tags: Consent decree, Informed consent, eConsent, Software, trial transparency, Research, Clinical trial

Iqvia describes the new platform as the marriage of eConsent with an authoring system – giving the clinical trial a framework for transparency and transformational change.

The software as service (SaaS) tool –Informed Consent Form Author –enables sponsors, sites, and contract research organizations (CROs) to view an online portal and produce informed consent forms (ICF) for delivery via eConsent or traditional paper.

Eric Delente, general manager of Patient Consent at IQVIA told us, “Simply put, we wanted the industry to know that there is an easy way to implement eConsent without cost and schedule implications.”

Trial transparency​, a movement in the clinical trial sector aimed to make research knowledge more readily available often relies on eConsent. Delente told us, “Trial transparency has been paramount for eConsent since its inception, as the rich, unalterable audit trails facilitate visibility and confidence into the consent process.”

“While the consent process must ultimately be the responsibility of the investigator, transparency is challenged by the traditional paper-based ICF process, where essentially a signed piece of paper and some notes are often all that are available,”​ he added.

Through the software, visibility into the ICF development process is available. Thus, the protocol to which the patient has consented to is also visible. “It's critical that all stakeholders in a clinical trial - including patients – be able to easily understand how a protocol and ICF has changed over the course of a study,” ​said Delente.

The ICF Author uses configurable workflows, checklists, and automated version control to manage and track authorship, review, and approval processes. According to Iqvia, this “dramatically improves”​ visibility and transparency leading to improved compliance.

Iqvia said CROs will be able to use the configurable workflows as a way of preventing accidental omissions before “they become a major problem.”

Research solutions restructured

The company also recently launched a new suite of virtual study options​ to challenge clinical research mindsets.

The virtual study suite powered by the Iqvia Study Hub, houses workflows, supports patient communications, stores documentation, captures study activity, and telemedicine visits.

Richard Staub, president of research and development solutions at Iqvia said at the time, “In a time where connectivity is transforming every industry, it’s time for one of the most critical functions in the biopharmaceutical space to evolve and take it to the next level.”

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars